Tardive dyskinesia engagement study
Part of Brain & nervous system clinical trials.
This study looks at how patients with tardive dyskinesia (a movement disorder) engage with their condition and treatment. It is for people who have not yet had treatment for tardive dyskinesia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with tardive dyskinesia
- You are 18 years old or older
- You have not had any previous treatment for tardive dyskinesia
- You are not currently enrolled in another research study
- You can give written consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an oral medication, NBI-1065890, can reduce the involuntary muscle movements caused by long-term use of antipsychotic drugs. It is for adults with moderate to severe tardive dyskinesia who also have a stable mental health condition like schizophrenia or bipolar disorder.
This study tests whether a non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS), targeted precisely using brain imaging, can safely reduce the involuntary movements caused by some psychiatric medications. If you have tardive dyskinesia, this treatment might help improve your motor symptoms.
This trial tests whether deutetrabenazine, a medication already used for tardive dyskinesia, can help people who also have intellectual or developmental disabilities. It aims to see if the drug reduces uncontrolled movements safely over 24 weeks.
This study tests if valbenazine helps adults with tardive dyskinesia whose symptoms continue even after taking or stopping another similar medication. Tardive dyskinesia involves uncontrollable movements from long-term use of certain mental health drugs.
This study looks at how people with treatment-resistant depression engage in their care. It does not test a new treatment but aims to understand patterns, which may help improve future care.
This study tests an experimental once-daily tablet for moderate-to-severe tardive dyskinesia, a condition causing uncontrollable repetitive movements. It aims to see if the drug is safe and reduces these symptoms over time.
Hear when a new Tardive Dyskinesia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.